Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Live webcasts for the events will also be accessible on Connect’s website in the Investors section under Presentations, Events & News at investors.connectbiopharm.com. An archived replay of the ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...